Lv1
30 积分 2024-03-29 加入
LAG-3 as the third checkpoint inhibitor
5小时前
待确认
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
22天前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
1个月前
已完结
T cell-engaging therapies — BiTEs and beyond
1个月前
已完结
Current landscape of CD3 bispecific antibodies in hematologic malignancies
1个月前
已完结
Endothelin 1 in cancer: biological implications and therapeutic opportunities
1个月前
已完结
JNJ-78306358, a First-in-Class Bispecific T Cell Engaging Antibody targeting CD3 and HLA-G
1个月前
已完结
HLA class I signal peptide polymorphism determines the level of CD94/NKG2–HLA-E-mediated regulation of effector cell responses
2个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
2个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
2个月前
已完结
皖公网安备34019202002308
